Artiva Biotherapeutics, Book Value Per Share vs. Revenue

ARTV Stock   10.48  0.63  5.67%   
Based on the key profitability measurements obtained from Artiva Biotherapeutics,'s financial statements, Artiva Biotherapeutics, Common may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Artiva Biotherapeutics,'s ability to earn profits and add value for shareholders.
 
Book Value Per Share  
First Reported
2010-12-31
Previous Quarter
(17.32)
Current Value
(18.19)
Quarterly Volatility
5.8567112
 
Credit Downgrade
 
Yuan Drop
 
Covid
Price To Sales Ratio is likely to drop to 3.18 in 2024. Days Sales Outstanding is likely to drop to 18.20 in 2024. At this time, Artiva Biotherapeutics,'s Net Interest Income is fairly stable compared to the past year. Interest Income is likely to climb to about 2.7 M in 2024, whereas Operating Income is likely to drop (32.2 M) in 2024.
Current ValueLast YearChange From Last Year 10 Year Trend
Return On Equity0.160.1709
Notably Down
Slightly volatile
For Artiva Biotherapeutics, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Artiva Biotherapeutics, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Artiva Biotherapeutics, Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Artiva Biotherapeutics,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Artiva Biotherapeutics, Common over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artiva Biotherapeutics,. If investors know Artiva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artiva Biotherapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.48)
Revenue Per Share
0.485
Quarterly Revenue Growth
(0.75)
Return On Equity
(0.44)
The market value of Artiva Biotherapeutics, is measured differently than its book value, which is the value of Artiva that is recorded on the company's balance sheet. Investors also form their own opinion of Artiva Biotherapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Artiva Biotherapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artiva Biotherapeutics,'s market value can be influenced by many factors that don't directly affect Artiva Biotherapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artiva Biotherapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Artiva Biotherapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artiva Biotherapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Artiva Biotherapeutics, Revenue vs. Book Value Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Artiva Biotherapeutics,'s current stock value. Our valuation model uses many indicators to compare Artiva Biotherapeutics, value to that of its competitors to determine the firm's financial worth.
Artiva Biotherapeutics, Common is number one stock in book value per share category among its peers. It is rated fifth in revenue category among its peers totaling about  4,046,883  of Revenue per Book Value Per Share. At this time, Artiva Biotherapeutics,'s Book Value Per Share is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Artiva Biotherapeutics, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Artiva Revenue vs. Book Value Per Share

Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Artiva Biotherapeutics,

Book Value per Share

 = 

Common Equity

Average Shares

 = 
8.28 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Artiva Biotherapeutics,

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
33.49 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Artiva Revenue vs Competition

Artiva Biotherapeutics, Common is rated fifth in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 414.66 Million. Artiva Biotherapeutics, holds roughly 33.49 Million in revenue claiming about 8% of equities under Health Care industry.

Artiva Biotherapeutics, Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Artiva Biotherapeutics,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Artiva Biotherapeutics, will eventually generate negative long term returns. The profitability progress is the general direction of Artiva Biotherapeutics,'s change in net profit over the period of time. It can combine multiple indicators of Artiva Biotherapeutics,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income277.2 K246.4 K
Net Interest Income2.5 M2.7 M
Interest Income2.5 M2.7 M
Operating Income-30.7 M-32.2 M
Net Loss-27.7 M-29.1 M
Income Before Tax-27.6 M-29 M
Total Other Income Expense NetM3.2 M
Net Loss-28.7 M-30.2 M
Income Tax Expense72 K75.6 K
Net Loss(2.96)(3.11)
Income Quality 1.65  1.73 
Net Income Per E B T 1.00  0.80 

Artiva Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Artiva Biotherapeutics,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Artiva Biotherapeutics, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Artiva Biotherapeutics,'s important profitability drivers and their relationship over time.

Use Artiva Biotherapeutics, in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Artiva Biotherapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Artiva Biotherapeutics, will appreciate offsetting losses from the drop in the long position's value.

Artiva Biotherapeutics, Pair Trading

Artiva Biotherapeutics, Common Pair Trading Analysis

The ability to find closely correlated positions to Artiva Biotherapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Artiva Biotherapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Artiva Biotherapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Artiva Biotherapeutics, Common to buy it.
The correlation of Artiva Biotherapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Artiva Biotherapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Artiva Biotherapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Artiva Biotherapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Artiva Biotherapeutics, position

In addition to having Artiva Biotherapeutics, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Currency Funds Thematic Idea Now

Currency Funds
Currency Funds Theme
Funds or Etfs investing in a single currency or combination of currencies from different countries in order to replicate respective foreign exchange markets. The Currency Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Currency Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Artiva Stock Analysis

When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.